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1.1 Introduction 
 
Constitutional chromosome balanced translocations occur in approximately one in 500 births, 
whom 6% are associated with clinical phenotypes (Warburton, 1991). Molecular 
characterization of such balanced translocations has been instrumental to decipher the genetic 
etiology of developmental anomalies and also to give contribution for annotation of human 
genome. 
Peter´s anomaly (OMIM 604229) is characterized mostly by embryological defects in the 
anterior segment of the eye which consists in central corneal opacity (leukomas - presence of 
white spot), defects of the inner layers of the cornea and a variable degree of lenticular and 
irido-corneal adhesions that leads to abnormal or even absence of anterior chamber. Secondary 
glaucoma is often associated with bilateral phenotypes. Moreover glaucoma represents the 
second major leading cause of blindness worldwide with an estimated 70 million people affected 
(Linda & Semina., 2011). 
Peter´s anomaly (PA) is predominantly inherited as autossomal recessive condition yet 
dominant and sporadic forms have also been documented. This condition may also occur as an 
isolated form or associated with systemic anomalies, mainly characterized by short stature, 
brachydactyly, developmental delay, dysmorphic facial features, cleft lip and palate among 
other defects mostly found in patients affected by Peters plus syndrome (OMIM 261540).  
PA is associated with a spectrum of developmental disorders affecting the anterior segment of 
the eye – anterior segment dysgenesis (ASD). This group of ocular disorders reveals an 
incomplete penetrance and variable expressivity which pinpoints to a complex etiology. To date, 
the genetic etiology underlying ASD remains elusive however important contributions have been 
made by linkage studies as well as through characterization of animal models. Molecular 
studies carried out in humans have identified haploinsufficiency of transcription factor coding 
genes affecting: paired box homeotic gene 6 (Pax6), homeobox protein PITX2 (Pitx2), 
homeobox protein PITX3 (Pitx3), forkhead box c1 (Foxc1), forkhead box c2 (Foxc2), forkhead 
box e3 (Foxe3), maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) Maf and 
eyes absent homolog 1 (Drosophila) Eya1 due to point mutations, deletions and insertions 
(Graw, 2004). In addition, recent findings reviewed by Reis and Semina (2011) have reported 
other anterior segment dysgenesis genes, ranging from signaling, adhesion and extracellular 
matrix related molecules. Most of these transcription factors are dose sensitive with a strictly 
spatio-temporal expression patterns regulated by a complex array of long range cis regulatory 
domains (Kleinjan, D & Heyningen V, 2005; Visel et al, 2007; Amiel et al, 2010). 
These distant cis regulatory element sequences are frequently highly conserved among 
vertebrates and can be located upstream, downstream or within introns of neighboring genes. 
Most often lie in gene deserts, located as far as 1.5 Mb from flanked target genes (Bofelli et al., 
2004; Kleinjan et al., 2004, Loots et al., 2008, and Nobrega et al., 2003). Furthermore these 
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conserved non-coding elements harbor clusters of TFBS which modulates gene expression in a 
tissue-specific manner. Important experimental evidences came from transgenic mice models 
that support the regulatory role of these conserved non-coding elements capable to drive 
reporter gene expression in a spatial and tissue-specific manner throughout development (Visel 
et al., 2007). 
Other etiologies such as chromosome balanced rearrangements have been implicated in such 
ocular defects. Fine mapping of breakpoints have elucidated pathogenic mechanisms 
implicated in gene haploinsufficiency through position effects that leave intact the “transcription 
unit”, yet causing misexpression regulation leading to abnormal ocular development. The 
breakpoint effect can disrupts long range regulatory elements from target promoters or can 
induced nuclear reorganization of chromosome derivatives leading to alteration of gene 
expression profiles (Kleinjan & Coutinho, 2009; David et al, 2009; David et al, 2013). 
Chromosome abnormalities such as translocations/inversions and genomic deletions and 
duplications have been associated with ASD phenotypes (reviewed by Mataftsi, et al, 2011). 
Molecular cytogenetic studies undertaken in a group of patients affected with aniridia 
(OMIM106210), mapped a set of breakpoints in Pax6 locus, precisely located at 150 Kb 
downstream from the promoter region (Linda & Semina., 2011; Kleinjan et al., 2001). This result 
was able to identify and characterize a novel cis regulatory region, with transcriptional 
regulatory function driving Pax6 expression on developing eye. 
Maf is a transcription factor that contains a leucine-zipper DNA binding domain and is located 
on 16q22-q23. It is an important key regulator for crystalline genes expression during lens fiber 
differentiation (Kawauchi et al., 1999). A breakpoint analysis of t(5;16) translocation in a family 
with cataracts and ocular anterior segment anomalies indicated that the translocation effect 
triggered a misexpression regulation of Maf gene by affecting a regulatory element located 
within a intron of Woww neighboring gene. Additionally a missense mutation in another family 
with lens and iris anomalies confirmed the role of Maf in lens development (Jamieson et al. 
2002). 
Foxc1 and Pitx2 genes are both expressed in same developing ocular structures, playing a role 
during chamber angle patterning, by regulating mesenchyme differentiation of presumptive 
trabecular meshwork and extracellular matrix remodeling that give raise to Schlemm´s canal.  
Pitx2 is a member of the bicoid class of homeodomain transcription factor family that maps on 
4p25. In humans and mice, Pitx2 deficiency leads to Axenfeld Rieger Syndrome (ARS) (Tümer 
et al., 2009), suggesting conservation of function for this gene during mammalian embryonic 
development. In mice, Pitx2 knockout results in embryonic lethality with ocular, craniofacial, 
dental, brain, heart, lung, body wall and other systemic defects observed. Ocular anomalies are 
observed in the Pitx2 
-/-
 homozygous but not in Pitx2 
+/- 
heterozygous animals and include arrest 
in anterior segment development, thickening of the mesothelial layer of the cornea resulting in 
enophthalmos, dysgenesis of the extra-ocular muscle and other systemic defects (Gage et al., 
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1999). Expression studies demonstrate that Pitx2 is strictly regulated and is expressed in neural 
crest derived periocular mesenchyme that contributes to the ocular and craniofacial tissues 
affected in ARS. Identification of genomic alterations found in 4p25 has suggested that a 
dosage sensitivity of Pitx2 may account for human ocular phenotypes. Both hypomorphic and 
over-activating alleles of Pitx2 can cause human ASD which indicates a dosage sensitivity of 
this transcription factor (Linda & Semina., 2011). Recent genomic characterization of a patient 
with Axenfled-Rieger syndrome (ARS) provided important clues about Pitx2 long range 
regulation. A deletion mapped on 4q25 located at 106 kb upstream from the intact Pitx2 
transcription unit revealed an evolutionary conserved non-coding element sequence. This 
genomic element was further characterized through a transgenic zebrafish assay which 
demonstrated a cis-ruption mechanism affecting a distant cis regulatory region of this gene 
which is able to recapitulate the endogenous Pitx2 expression, consistent with embryological 
tissues affected by ARS (Volkman et al., 2011). 
Foxc1 is a transcription factor with a forkhead/winged-helix DNA binding domain and maps on 
6p25. In the developing eye, Foxc1 is primarily expressed in the periocular and pre-endothelial 
mesenchyme, cornea, conjunctival epithelium and trabecular meshwork (Graw, 2004). In 
corneas of Foxc1
-/-
 mice the epithelium is thickened, the stroma is disorganized and there is no 
differentiation of the endothelium. The lens fails to separate from the cornea and as result there 
is a complete absence of the ocular anterior chamber (Kidson et al., 1999). Foxc1
-/+
 
heterozygous mice are viable and have milder anterior segment defects than Foxc1
-/-
 mice 
(Hong et al., 1999, Smith et al., 2000). 
Development of periocular mesenchyme derived tissues is abnormal in Foxc1
-/+
 mice. 
Abnormalities include iris malformations, iridocorneal adhesions and corneal opacity. Angle 
malformations include small or absent Schlemm´s canal and hypoplastic, compressed 
trabecular meshwork. Abnormal iridocorneal angle structures have a paucity of extracellular 
matrix proteins including collagen and elastin and cells that have the appearance of 
undifferentiated precursor cells. 
Patients with mutations in Foxc1, have a spectrum of ASD phenotypes and glaucoma. Genomic 
duplications and deletions mapped on 6p25 locus have been implicated in iridogoniodysgenesis 
type I, IRID1 (OMIM 601631), an ASD disorder characterized by defects in iris associated with 
glaucoma (Lehmann et al., 2002., Nishimura et al., 1998).  
Interestingly, a molecular characterization of familial balanced translocation t(1;7) associated 
with an isolated form of Peters anomaly demonstrated that 1q41 breakpoint is located closest 
from an evolutionary conserved non-coding region. This region is located 500 Kb apart from 
transforming growth factor, beta 2 (Tgfb2) transcription unit where most likely can act as an 
enhancer, driving Tgfb2 expression in developing eye (David et al., 2003). 
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A recent study has shown that Tgfb2 is the upstream factor regulating Pitx2 and Foxc1 
transcription factors. In mice, a conditional targeted inactivation of Tgfb2 signaling showed 
malformed anterior segment structures, reminiscent of Peter´s anomaly phenotype along with a 
decreased phosphorilation of transducing effector molecule Smad2 and also by donwregulation 
of Pitx2 and Foxc1 expression in stroma and inners layers of cornea (Iwao et al., 2009). 
Despite TGF has 3 mammal isoforms, only Tgfb2 knockout mice have shown abnormal ocular 
morphogenesis characterized by thin corneal stroma, absence of corneal endothelium, fusion of 
cornea to lens (a Peter´s like phenotype) and accumulation of hyaline cells in vitreous 
(hyperplastic primary vitreous) (Saika et al., 2001; Ittner et al., 2005 & Tovar-Vidales et al., 
2011). In addition several other defects were detected and characterized, including heart, 
craniofacial defects and abnormal bone formation (Sanford et al., 1997). 
In addition to that, expression studies during ocular development have shown similar Tgfb2 
expression patterns observed among humans and mice which pinpointed to a conserved 
function of this molecule among mammals (Firsova et al., 2011). Moreover in mice, Tgfb2 
deficiency or overexpression results in anterior segment anomalies, which supports a dosage 
sensitivity mechanism that regulates properly Tgfb2 throughout anterior segment development. 
1.2 propose 
 
Here we aim to perform molecular characterization of a female proband, with a de novo 
t(11;18)(q23.3;q11.2) balanced translocation associated with a syndromic form of Peter´s 
anomaly, (ectopia lentis and CNS abnormalities). Fine mapping of breakpoints and further 
assessment of gene expression profile by array and RT-qPCR will contribute to elucidate the 
functional role of breakpoint surrounding genes in development and molecular pathogenesis of 
anterior segment of the eye and also give a contribution in annotation of the human genome. 
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2.1 Patient samples 
 
The proband carrying a de novo t(11;18) balanced translocation is a child from a non-
consanguineous Kurdish family recruited in a medical clinical genetics in Finland. The relatives, 
father, mother do not manifest clinical phenotypes. In addition a group of subjects affected with 
Peter’s anomalies was included in this study. These patients are from Hungarian and 
Portuguese families. 
2.2 Cell culture 
 
Previously, peripheral blood samples were collected and lymphocyte cell transformation was 
performed as described by Neitzel (1986) and according to standard protocols at the National 
Institute of Health, Dr. Ricardo Jorge (Department of Genetics, Lisbon). These were cultured in 
RPMI1640® Dutch modified medium, supplemented with 20% fetal bovine serum heat 
inactivated 3mM glutamine and 2% of penicillin (10000 UI/ml) and streptomycin (10000 mg/mL), 
maintained at 37ºC, 5% CO2 in open culture conditions. The human lens epithelium cell line, 
H36CE (kindly gifted by Dr. Alan Prescott, lens laboratory, Dundee University) was cultured in 
DMEM Glutamax® medium (Gibco) with 10% fetal bovine serum heat inactive (Gibco) and 
supplemented with 1% of penicillin/streptomycin. 
2.3 Flow sorting of derivative (der) chromosomes 
 
Chromosomes in metaphase were flow sorted by a dual laser FACS Vantage (Becton 
Dickinson) starting from a LCL culture in log phase from index case (translocated patient), 
treated with 0,05 mg/ml colcemid (final concentration) for 16 hours carried out according to 
standard protocols described in Unger et al., (2010). Of each derivative chromosomes, 27000 
for der(11) and 40000 for der(18) were sorted into PCR tubes for genomic amplification. The 
sorting procedure was carried out at CHROMBIOS Molecular Cytogenetics (Raubling, 
Germany). 
2.4 DNA extraction, genomic amplification, array painting and 
amplification of junction fragments 
 
Genomic DNA was prepared from LCL established from peripheral blood mononuclear cells 
from translocated patient, DGH041689 using QIAamp® DNA blood extraction midi kit, from 
QIAGEN (Hilden, Germany) carried out according to the manufacturer´s instructions. For 
assessment of quality control, DNA was analyzed in Nanodrop® and also by electrophoresis in 
a 0.8% agarose gel. 
For genomic amplification of each flow sorted derivative chromosomes, approximately 5,000 
were used in 10µl of sorting buffer. Amplification was performed using the REPLI-g® Midi Kit, 
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from QIAGEN (Hilden, Germany) according to the manufacturer´s instructions for laser 
microdissected cells. The reaction volume was increased to 77,5 µl. Purification of each 
derivative chromosome genomic amplicons were carried out as previously described (David et 
al., 2013) (Purification of REPLI-g amplified DNA using the QIAamp DNA Mini Kit). The quality 
control of the amplicons was evaluated by electrophoresis in a 0.8% agarose gel and by 
amplification of a control fragment (350 bp in size). 
The high resolution oligonucleotide array painting was performed using the Genome-Wide 
Human SNP 6.0 array (Affymetrics
®
, Santa Clara, CA, USA) according to the manufacturer´s 
instructions at Gulbenkian Institute of Science (Oeiras, Portugal). This array contains more than 
1.8 million SNP and CN marker probes with a marker spacing average of 680 bp. 
Each purified genomic amplicons of flow-sorted derivative chromosome DNA samples was 
diluted in low TE buffer, with a concentration ≥ 50 ηg/µl. Total amount of 500 ηg was required 
for each array preparation. Briefly, genomic DNA was digested with Sty I and Nsp I restriction 
enzymes, Sty I and Nsp I fragments were ligated with specific adaptors for PCR amplification. 
Fragmentation, biotin end-label of DNA samples and loading and hybridization into microarray 
were carried out using Human SNP 6.0 Sty I/Nsp I assay, (Affymetrics, Santa Clara, CA, USA). 
Washing and staining steps were performed according to human SNP 6.0 P_450 protocol, 
according to manufacturer´s instructions (Affymetrics, Santa Clara, CA, USA). Finally microarray 
was scanned and data was validated with BIRDSeed algorithm. The data were analyzed using 
ChAS software from Affymetrics. The chromosome positions where the log2ratios change from 
high to low ratio (or vice versa) defines potential alterations or CNVs. Potential CNVs were 
queried in the Database of Genomic Variants (DGV, 
http:/projects.tcag.ca/variation/?source=hg19). 
To narrow down the breakpoints within the region delimited by FISH and array analysis, a set of 
primers were designed and used to amplify the presence of chromosome markers. 
Oligonucleotides and amplification conditions used for this goal are summarized in table 1.1 
The der (11) and der (18) junction fragments were amplified with the primer pairs OAF-
5F/AC110583-5R and AP000679-2R/AC110583-8F, respectively. The primer sequences and 
amplification conditions are summarized in table 1.2. The resulting junction fragments were 
sequenced by automated direct dideoxy sequencing. PCR fragments were purified by 
centrifugation through centricon columns YM-100K (Millipore, Billerica, MA). Sequencing was 
performed by the BigDye® terminator cycle sequencing kit with the PCR primers and reaction 
products were separated on the automated sequencer ABI 3130XL according to manufacturer’s 
instructions (Applied Biosystems, Foster City, CA, USA). The sequencing data were aligned to 
the human genome assembly GRCh37/hg19. 
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2.5 RNA isolation and expression analysis of candidate genes 
 
In order to reduce variation due to minor differences in cell culture conditions, lymphoblastoid 
cell lines (LCLs) were grown under previously established standard conditions as previously 
described (David et al., 2013). Total cellular RNA was isolated from 1,0x 10
7
 cells using 
QIAamp
®
 RNA blood extraction kit according to manufacturer´s instructions (Qiagen). In 
addition, RNAse-free DNAse I treatment was performed by incubating RNA samples for 30 
minutes at room temperature. Assessment of quality and quantity for extracted RNA was 
determined by Agilent 2100 Bioanalyzer
®
 (Palo Alto, CA, USA) and also with Nanodrop
® 
ND-
1000 (Thermo Scientific, Wilmington, DE, USA). The amount of 2 µg of RNA was reverse 
transcribed (RT) into cDNA with Superscript First-Strand kit and random hexamers, according to 
manufacturer´s instructions (Life Technologies, Carlsbad, CA, USA). The RT reactions were 
diluted with 60 µl of DEPC treated H20 as described previously and stored at -80ºC. 
Assessment of gene expression levels in LCL of the proband was performed using the Human 
Gene 1.0 ST array from Affymetrics®. The following steps of labelling, hybridization, washing, 
staining and scanning of the arrays were performed according to the manufacturer´s 
instructions at the Gulbenkian Institute of Sciences (Oeiras, Portugal). Data analysis was 
carried out according as previously described (David et al., 2013). 
For validation of Human Gene 1.0 ST array data, Real time RT-PCR assays were performed 
with TaqMan
®
 Gene Expression Master Mix, according to manufacturer´s instructions (Applied 
Biosystems, Foster City, CA, USA). Primers and probes were pre-designed according to 
inventoried TaqMan gene expression assays. The efficiency of each PCR assay was previously 
tested with serial tenfold dilution of cDNA as described previously by Livak and Schmittgen, 
(2001). All RT-PCR reactions were set up in a final volume of 15 µl. Each sample was run in 
triplicate in 96 well plates into ABI 7500 real time PCR system device, set up for default thermal 
conditions. For each plate, the amplification plots were first analyzed and threshold cycle was 
set up manually. The 2
ΔCt
 method was used to measure fold change on gene expression levels 
in LCLs for the following gene transcripts: OAF (TaqMan assay: Hs00420156_m1, exon junction 
3 to 4), POU2F3 (TaqMan assay: Hs00205009_m1, exon junction 5 to 6), ARHGEF12 (TaqMan 
assay: Hs00209661_m1, exon junction 30 to 31) PVRL1 (TaqMan assay: Hs01591978_m1, 
exon junction 4 to 5) CYP1B1 (TaqMan assay: Hs02382916_s1, exon 3) and EDIL3 (TaqMan 
assay: Hs00174781_m1, exon junction 2-3). Normalization of gene expression data was 
performed relative to mean ratio of Ct values of DIDO1 (Hs-00223101_m1) and GUSB (Hs-
02827277_g1). To test whether fold change is different between translocated patient relative to 
LCLs from a control group, a two tailed T test was performed with a p value <0, 05. A group of 
15 LCLs from unrelated subjects were used as controls. 
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2.6 Mutational screening of CYP1B1 
 
Genomic DNA was prepared from peripheral blood samples from a group of subjects affected 
with Peter´s anomaly using QIAamp
®
 blood DNA extraction midi kit, (Qiagen) according to 
manufacturer´s instructions. These DNA samples were further assessed for quality by Nanodrop 
ND-1000 using 260:280 absorbance ratio values. Integrity was checked by electrophoresis in a 
gel with 0.8%. 
 
The entire coding sequence of CYP1B1, exon-intron junctions, untranslated exon I and a 
fragment spanning the 5´UTR region were amplified for mutation screening. Oligonucleotides 
used as primers and amplification conditions are summarized in supplementary table 1.5 
Sequencing was performed by automated direct dideoxy sequencing. PCR fragments were 
purified by centrifugation through centricon columns YM-100K (Millipore, Billerica, MA). 
Sequencing was performed by the BigDye
®
 terminator cycle sequencing kit with the PCR 
primers and reaction products were separated on the automated sequencer ABI 3130XL 
according to manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). The 
sequencing data was analyzed manually and also with blast tool provided by Ensembl genome 
browser and according with human genome reference assembly GRCh37/hg19. 
2.7 Analysis of Breakpoint Regions  
 
Sequence from junction fragments were aligned with blast tool from Ensembl genome browser 
(www.ensembl.org). Repetitive DNA sequences of low complexity were screened by repeat 
masker tool available on UCSC (genome.ucsc.edu) (the reference sequence is the current 
human genome assembly GRCh37/hg19). Comparative genomic sequence analysis was 
achieved by VISTA genome browser. Software settings were defined by a window size of 100 
bp length and a minimal sequence conservation identity above 70% 
(www.genome.lbl.gov/vista). UCSC and RefSeq annotation tracks were used to identify 
assigned genes located around the breakpoint regions. 
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3.1 Breakpoint mapping at nucleotide resolution 
 
Mapping the breakpoints of chromosome rearrangements has been a successful approach for 
the identification of disease causing genes and to study the mechanism of chromosome 
rearrangement. In the last decades, identification of translocation breakpoints have been 
achieved with FISH using labeled large insert clones yet with low resolution and time 
consuming. Presently, array painting provides higher resolution and faster way to identify 
chromosome translocation breakpoints. 
Previously, cytogenetic analysis of GTL-banded metaphase chromosomes from the proband 
t(11;18), revealed a de novo apparently balanced chromosome translocation between 
chromosomes 11 and 18 [t(11;18)(q25)(q11.2)]. Therefore, with the aim to narrow down the 
breakpoints, FISH mapping of the breakpoints was carried out. A number of BAC clones 
encompassing the breakpoints were FISH mapped on metaphase chromosome spreads from 
proband.  
Fine mapping of translocation breakpoints were carried out by array painting with genome 
amplicons from derivative flow sorted chromosomes. Analysis of array data, localized 
chromosome 11 breakpoint within an approximately 3.3 kb fragment, between copy number 
(CN) markers C-051RG (120,126,723) and C-051RL (120,130,006) whereas the chromosome 
18 breakpoint was localized within a 1.5 kb fragment delimited by the CN markers S-2NVJXA 
(20,173,998) and C-0FQO1 (20,175,539) of the Genome-Wide Human SNP Array 6.0 
(reference genome assembly GRCh37/hg19). The array result was confirmed by the presence 
of specific PCR fragments in the two derivative flow sorted chromosome genome amplicons. 
Table 1.1 Oligonucleotides and amplification conditions used for refinement of the breakpoints. 
PCR fragment Designation Primer sequence (5` - 3`) Primer localization PCR 
size 
(bp) 
Chromosome 11 breakpoint region     
C-051QQ 
AP000679-3F TAT TCA GCG AGA AGA TTC AGC C 120098056 
 AP000679-2R GTA CCC AGA GAG GGG TCA GC 120098377   
C-051RG 
AP001150-4F CTC CAT TTA GCC CCT CAG TGT 120126491 
 AP001150-5R AGG GAC GGT AAC TCA GGT GAG 120126736   
C-051RL 
AP000679-6F CCT GAG GTT GGT GAT GTT GAC 120129920   
AP000679-7R GGA GTT GGG AGG TCT GAG TCT 120130259   
Chromosome 18 breakpoint 
region         
S-2NVJXA  AC110583-1F ATG AAT GGA CAG ACT GAG GCC 20173814 
 
S-2N5KQA 
AC110583-3F GCC TGG ATG ACA GAG TGA CTG 20175980   
AC110583-2R AAG AAG CAG CAA GAA GTG GGT 20176127   
C-0FQP1 
AC110583-4F GAG ATC ATC ACA ATG GCA TGT T 20221568 
 AC110583-5R GGG AGG TGA GAG CAA AGA ACT A 20221850   
Polymerase chain reaction specific fragments were carried out from genomic amplicons of derivative 
chromosomes. Annealing temperature was 60ºC for all fragments and amplification was carried out for 25 
cycles. 
As shown in figure 1.1, the junction fragments were further amplified and sequenced. Sequence 
alignments were carried out between junction fragments and the corresponding reference 
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genome (current human genome assembly h19/GRCh37). This analysis localizes the 
chromosome 11 breakpoint at position g. 120,097,868_120,097,869 within intron 3 (IVS3) of 
OAF (Out of first protein homolog). Analysis of genomic repeats (Ensembl genome browser) 
shows type I transposon/LINE (120097837-120098137) with 301 bp size within the 11q23.3 
breakpoint. This breakpoint is flanked upstream by TRIM29 (119,981,983-120,056,237) and 
PVRL1 (Poliovirus receptor-related 1) (119,494,120-119,599,794) whereas downstream it is 
flanked by POU2F3 (POU class 2 homeobox 3) (120,107,349-120,190,653), TMEM136 
(Transmembrane protein 136) (120,195,838-120,204,391) and ARHGEF12 (Rho guanine 
nucleotide exchange factor 12) (120,207,787-120,360,645) (Fig 2A). 
Table 1.2 Oligonucleotides used for amplification of junction fragments 
Chr  designation   
5´-3´ 
sequence   Fragment Genomic localization 
11 OAF-5F CCACCTCCCATCCACACCT JuFg der 11 120097267 
18 AC110583-5R GGGAGGTGAGAGCAAAGAACAA JuFg der 11 20221850 
11 AP000679-2R GTACCCAGAGAGGGGTCAGC JuFg der 18 120098377 
18 AC110583-8F CAGCCTACCCCTTACTTTTCAC JuFg der18 20220241 
 
This genomic sub-band 11q23.3 has been characterized as breakpoint prone region, described 
by several genomic aberrations like 11qter deletion syndrome (Jacobsen syndrome) or the 
recurrent t(11;22) translocations. To date several fragile and non- fragile sites at 11q23.3 
(FRA11) have been screened and involved in genesis of DNA breakage. 
The 18q11.2 breakpoint, at position g. 20,220,714_20,220,715, localizes in a gene poor region 
flanked by repeats, LTR79 (20,220,183-20,220,526) and MER2 type II transposon (20,221,012-
20,221,101). This breakpoint is flanked upstream by GATA6 (19,749,404-19,782,491) and 
CTAGE1 (19,993,573-19,997,878) whereas downstream it is flanked by RBBP8 at position g. 
20,378,224-20,606,451 (Fig 3) (The reference human genome is the assembly version 72.37, 
GRCh37). 
Breakpoint analysis indicates 13-bp duplication in the sequence of chromosome 11 on der (18) 
whereas on chromosome 11 breakpoint the sequence is contiguous (figure 1.1). Therefore the 
proband´s karyotype revised is 46, XX, apparently a de novo balanced 
t(11,18)(11q23.3)(18q11.2) translocation. Both parents have normal karyotypes. 
The 18q11.2 breakpoint region was further analyzed through comparative genomic VISTA 
analysis. This analysis identified eight conserved non-coding element sequences (CNE) across 
18q11.2 breakpoint spanning sequence with 100 kb size. This breakpoint is flanked by two CNE 
(Fig 4). 
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Figure 1.1 Amplification and DNA sequence of the der (11) and der (18) junction fragments. (a) 
Amplification of the translocation junction fragments. A 1763 bp (left) and a 956 bp (right) PCR junction 
fragments were obtained from the der (11) and der (18) chromosomes respectively. The translocation 
junction fragments are indicated by black arrows. (b) Sequencing of PCR amplified junction fragments. 
Black arrows indicate the breakpoints position at nucleotide level. Electropherograms are showing 11q23.3 
breakpoint sequence in reverse orientation whereas 18q11.2 is in forward orientation. Schematic diagram 
shows chromosome specific primers to PCR-amplify junction fragments (C) Sequence alignment between 
junction fragment sequences and human genome reference (chromosome 18 sequence is given in grey 
black, whereas the chromosome 11 sequence in black). The 13 bp duplication in the chromosome 11 
sequence of der (18) is boxed whereas the homologous pentapalindromic GACATCCA at the translocation 
breakpoints are underlined. The position of the breakpoints at the DNA sequence level are indicated 
(current genome assembly GRCCh37/hg19).  
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Figure 1.2 Overview of the two breakpoint regions. The affected chromosome regions are highlighted 
by red vertical lines whereas arrows indicate the position of breakpoints. GenBank accession numbers of 
the breakpoints spanning sequences are given above the maps. (a) Ideogram of chromosome 11, with 
physical map across the breakpoint. Horizontal lines with arrowheads indicate the position of genes in 
sense (above the map) or antisense (below the map) orientation. Location and genomic organization of 
OAF is indicated. Numbered vertical lines indicate exons. The reference sequence is the current genome 
assembly GRCh37/hg19. (b) Ideogram of chromosome 18, with physical map across breakpoint region. 
Horizontal lines with arrowheads indicate the position of genes in sense (above the map) or antisense 
(below the map) orientation. The vertical black arrow indicates the location of breakpoint mapped in this 
study. The reference sequence is the current genome assembly GRCh37/hg19. 
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Figure 1.3 Genomic organization of evolutionary conserved non-coding element sequences across 
chromosome 18q11.2 breakpoint region. (a) Distribution of conserved non-coding element sequences 
(CNE) among vertebrates in a 100 kb fragment spanning 18q11.2 breakpoint region. Arrow indicates the 
location of breakpoint (Human genome assembly is GRCh37/h19). (b). VISTA plot analysis of 100 Kb 
fragment (g. 20,140,000-20,240,000). Comparative genomic analysis between human genome reference 
and chicken, rat and mouse genomes, depicted on right side with a conservation identity above 80% and 
sliding window of 100bp. Below the plot an arrow indicates the location of the breakpoint surrounded by 
two proximal conserved non-coding element sequences (CNE 7 and 8) out of 8. 
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3.2 Expression analysis of candidate genes 
 
As recently reported by David et al. (2013) expression studies were undertaken by array 
profiling and validation by TaqMan
®
 real time RT-PCR technology. 
Assessment of gene expression profile using Human Gene 1.0 ST expression array from 
Affymetrics
®
 in LCLs of the proband carrying t(11;18) indicated an approximately 3-fold 
reduction in expression levels of cytochrome P450, family 1, subfamily B, polypeptide 1, from 
chromosome 2p22.2 (CYP1B1) whereas the EGF-like repeats and discoidin I-like domains 3, 
from chromosome 5q14 (EDIL3) showed a 5-fold increase in proband relative to control. 
Expression levels of CYP1B1 are not statistically significant whereas for EDIL3 is significant 
with a p value of 0.001. 
We propose that a position effect mechanism could lead to dysregulation of candidate genes, 
located within a 3 Mb window from chromosome 11 breakpoint. Interestingly, both Poliovirus 
receptor-related 1 (PVRL1) located about 500 Kb upstream and Transmembrane protein 136 
(TMEM136) located 98 Kb downstream from 11q23.3 breakpoint, indicated approximately 1.2-
fold increase in LCLs of the proband against control. The expression levels of OAF (Out of first 
protein homolog), disrupted by breakpoint as well as the closest genes from breakpoint were 
not considerably different from control (table 1.3). 
Subsequently, the expression level of candidate genes, CYP1B1, EDIL3 and PVRL1 in LCL of 
the proband as well as in control LCLs from 15 unrelated subjects were determined by real time 
RT-PCR. The relative gene expression levels were normalized against mean ratio of two 
reference genes Death Inducer-Obliterator 1 (DIDO1) and Glucuronidase, Beta (GUSB). While 
DIDO1 shows mean Ct values of 24 with a SD of 0.5, the GUSB presents a mean Ct value of 28 
with SD of 0.5. Therefore the stability for gene expression levels was similar for both genes, 
however the mean Ct values are quite different and the mean ratio between these two control 
genes may express more accurately a wide range of expression data. 
The mean relative expression level of CYP1B1 transcript comprising exon 3 in the proband 
compared with control group was 16.5 fold lower (0,079 vs 1,31, P=0,0014) whereas EDIL3 
transcript comprising exon 2-3 junction sequence indicated a fold change by 104 higher in 
proband relative to control (3,56 vs 0,034, P= 0,034). Finally the relative gene expression level 
of PVRL1 transcript comprising 3-4 junction sequence presented a 3,5 fold increase relative to 
control (3,11 vs 0,87) not statistically significant. The gene transcripts Out At First Protein 
Homolog (OAF) and POU Class 2 Homeobox 3 (POU2F3) were also assayed by real time RT-
PCR technology and fold change values in proband relative to control were determined (table 
1.3). These values are different from those obtained by array, yet without statistical significance. 
While for Rho Guanine Nucleotide Exchange Factor (GEF) 12 (ARHGEF12) transcript, level of 
gene expression presented similar values compared with array (table 1.3). Despite that RT-
qPCR data confirmed the array, these significant differences between expression array and real 
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time RT-PCR technique could be due to the sensitivity of real time PCR and/or with different 
hybridization probes covering different exon junction sequences. 
In the chromosome 18 breakpoint, the flanked genes Cutaneous T-Cell Lymphoma-Associated 
Antigen 1 (CTAGE) and Retinoblastoma Binding Protein 8 (RBBP8) presented fold change 
values in LCLs of proband relative to controls by -0.24 and 0.32. These fold change values 
suggest that the translocation breakpoint is not affecting gene expression (table 1.3). 
Additionally we used a group of patients affected with peters anomaly from different families in 
order to provide hints about pathogenesis and genetic etiology of Peter´s anomaly. Therefore 
candidate genes were also analyzed with LCLs from this group of patients with peters anomaly 
(Figure 1.4). Expression analysis was quantified only with RT-qPCR. The relative expression 
values for CYP1B1 transcript in LCL of proband relative to this group was 12,5 fold lower 
whereas EDIL3 indicated a fold change by 83 higher in proband relative to mean relative 
expression of peters group. In addition, patient no 8 showed a 40 fold increase of relative 
expression of EDIL3 when compared with Peter´s group. 
The mean relative expression of PVRL1 transcript in the proband relative to PA group was 
higher by 2.9 fold. Finally, relative expression data either for OAF and POU2F3 was 1.4 fold 
reduction and 1.5 fold increased respectively in proband relative to PA group. Interestingly the 
patients 8 and 9 presented relative expression levels very lower compared with LCLs of peters 
patients group. 
3.3 Candidate genes are expressed in human lens epithelium 
 
In order to understand the functional role of candidate genes during lens development, we 
addressed this question by assessing additional quantification of relative gene expression with 
RNA from a relevant physiopathological human lens epithelium cell line, H36CE2. Conversely 
as shown in RNA from LCLs, EDIL3 gene transcript is highly expressed in human lens 
epithelium cell line with an increase of 4.43-fold relative to DIDO1 reference gene. CYP1B1 
(1.09), OAF (0.46) and PVRL1 (0.44) transcripts have shown only moderate levels of gene 
expression. Conversely POU2F3 gene transcript is not expressed in human lens epithelium cell 
line (figure 1.4). 
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Figure 1.4 Relative expression levels of candidate gene transcripts. (a) Bar graphs depicting the relative expression of CYP1B1 and EDIL3 and PVRL1 transcripts. (b) Bar 
graphs depicting the relative expression of remaining OAF and POU2F3 genes from 11q23.3 region. Expression levels of all fragments were normalized to the mean ratio of 
two controls, DIDO1 and GUSB. Fold change relative to reference is given in 2
ΔCt
. Error bars represent standard deviation. GP1 to GP9 are subjects affected by peters 
anomalies, and C1 to C15 are control LCLs from unrelated subjects. (c) Bar graphs depicting the relative expression of candidate gene transcripts in human lens epithelial cell 
line H36CE2. 
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 Table 1.3 Summary of the expression data obtained by two different methods  
 
Chromosome localization 
 
Index case 
 
Descriptive statistics 
Gene Symbol  Breakpoint distance (bp) Assay NEL Log2 FC 
 
Average Min  Max SD 
11q23.3 Breakpoint Region         
 
        
PVRL1 498 Array 7.35 
a
1.19 
 
6.16 5.31 6.99 0.47 
  
RT-qPCR 4-5 NA 
b
3.5 
 
0.874 0.261 2.296 0.53 
TRIM29 41.6 Array 6.18 
a
0.26 
 
5.93 5.37 6.5 0.31 
OAF  disrupted (IVS3) Array 6.81 
a
-0,124 
 
6.93 6.33 7.72 0.41 
  
RT-qPCR 3-4 NA 
b
-1,7 
 
0.21 0.023 0.547 0.15 
POU2F3 9.5 Array 6.5 
a
0.25 
 
6.25 5.47 6.92 0.39 
  
RT-qPCR 5-6 NA 
b
1.7 
 
0.29 0.02 1.23 0.3 
TMEM136 98 Array 6.43 
a
1.17 
 
5.26 4.55 6.24 0.524 
ARHGEF12 110 Array 8.92 
a
0.58 
 
8.33 7.61 8.95 0.38 
  
RT-qPCR 30-31 NA 
b
1.6 
 
0.376 0.248 0.773 0.1 
18q11.2 Breakpoint Region         
 
        
GATA6 471.3 Array 6.28 
a
-0,5 
 
6.78 6.09 7.71 0.54 
CTAGE1 222.8 Array 2.99 
a
-0,24 
 
3.22 3.02 3.46 0.13 
RBBP8 157.5 Array 8.87 
a
0.324 
 
8.54 7.46 9.22 0.58 
CYP1B1  (2p22.2) NA Array 5.75 
a
-3,18 
 
8,93 7.46 10.93 1.04 
  
RT-qPCR 3-3 NA 
b,c
-16,50 
 
1.31 0.24 4.9 1.2 
EDIL3  (5q14.3) NA Array 8.57 
a
5.1 
 
3.51 2.95 4.33 0.4 
    RT-qPCR 2-3 NA 
b,c
126   0,001 1.5x10^-5 0.14 0.0037 
NEL: normalized expression level. 
a
 Analyzed as two groups. 
b
 Fold change of the expression levels of candidate genes was normalized against mean ratio of DIDO1 and 
GUSB relative to control group. 
c
 Indicates statistical significance at P value ≤0.05. NA not applicable, ND not done. 
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3.4 Mutational analysis of CYP1B1  
 
The CYP1B1 maps on chromosome 2p22-p21 at GLCA3 locus and encodes a member of the 
cytochrome P450 superfamily of dioxin-inducible genes. CYP1B1 encodes for a 
monooxygenase which catalyzes reactions involved in detoxification of xenobiotics, synthesis of 
steroids and other lipids.  
Furthermore, several studies performed during chicken and murine development have revealed 
a predictive role in ocular development. In 2004, Stoilov et al, examined the murine embryonic 
expression of CYP1B1 by whole mount in situ hybridization, having found a spatio-temporal 
expression pattern consistent with ocular structures affected by primary congenital glaucoma 
and ASD phenotypes such as Axenfeld Rieger and Peter´s anomalies. By other hand a 
functional analysis of CYP1B1 deficient mice performed by Libby et al, 2003 revealed 
dysgenesis of trabecular meshwork and absence of Shlemm´s canal, both ocular structures with 
a functional role in regulation of intraocular pressure, affected in PCG and ASD human 
phenotypes. Several studies have shown that CYP1B1 mutations are associated with PCG as 
well as in minor extension with Peters and Axenfeld Rieger anomalies. 
In this context and due to reduction of CYP1B1 mRNA levels in proband, we thought that a 
deletion or a nonsense mutation might account for reduced CYP1B1 gene expression. 
Therefore we screened the entire coding and regulatory 5´region of CYP1B1, yet we did not find 
any pathogenic mutations associated with ocular phenotypes. 
In addition we included plus 15 peters patients from different families (described in table 1.4) 
and we screened in the same way the CYP1B1 with the goal to understand the role of CYP1B1 
in this group of patients affected with Peter´s. Sequencing data indicated two previously 
mutations being one 13-bp homozygous deletion affecting a female from a Portuguese family. 
This mutation was previously reported by Stoilov et al., 1997. This deletion removed nucleotides 
1410 to 1422 from exon 3 of the gene and resulted in a frameshift that truncated the open 
reading frame by creating a premature stop codon (TGA) 203 bp downstream of the deletion. 
The second mutation was found in two relatives, father and son from a Brazilian family and is 
considered a missense heterozygous 4046T-A transversion in exon 2, resulting in a tyr81-to-
asn (Y81N) substitution. This mutation was previously reported by Melki et al, 2004 in two 
unrelated French Caucasian patients with adult-onset primary open angle glaucoma. Based on 
functional analysis of enzymatic activity of cytochrome this mutation was reported as 
hypomorphic allele having presented an intermediate activity between pathogenic mutations 
and the SNP coding haplotype with the most reduce activity. 
Apart from these mutations we detected only coding non synonymous single nucleotide 
polymorphisms (rs10012, rs1056827, rs1056836, rs1056837 and rs1800440) in the rest of 
patients including proband carrying t(11;18). These 5 common SNPs resulted in different 
haplotypes that have been functionally characterized by Chavarria-Soley et al., 2008.  
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Additionally a recent publication, conducted in a southern Indian population indicated a strong 
functional association with a regulatory polymorphism rs2567206 (T2805C) and PCG cases 
harboring homozygous CYP1B1 coding mutations. Conversely, it was not detected a significant 
association with non-congenital forms of glaucoma. Furthermore this polymorphism was 
functionally assayed by a CAT reporter system in TM3 trabecular meshwork cell line and results 
clearly showed a considerably reduction of promoter activity in CCG haplotype whereas TCG 
showed a protective haplotype. Furthermore this region was analyzed by TFBS scan software 
tools which suggests that promoter has putative binding sites for transcription factors such as, 
PBX-1, GATA-1, and NKX-2, encompassing the rs2567206 polymorphism. These transcription 
factors are required for the correct patterning during development and could be involved in 
regulation of trabecular meshwork (Chakrabarti et al., 2010). 
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Table 1.4 Single Nucleotide Polymorphism Based Haplotypes Associated with CYP1B1 Mutations 
       
Haplotype (dbSNP) 
Patient 
 
Diagnosis 
Country of 
origin Mutation  
Amino acid 
change  
rs
2
5
6
7
2
0
6
* 
 r
s
2
5
5
1
1
8
8
 
 r
s
2
6
1
7
2
6
6
 
 r
s
1
0
0
1
2
 
 r
s
1
0
5
6
8
2
7
 
 r
s
1
0
5
6
8
3
6
 
 r
s
1
0
5
6
8
3
7
 
 r
s
1
8
0
0
4
4
0
 
Families 
 
         
               
4390 - II.1 
(Proband) 
 
PA+EL  Filand NF 
 
C/T G/A C/T C/G G/T C C A 
I.2 (Mother) 
  
Filand NF 
 
T A T G T C C A 
I.1 (Father) 
 
  Filand NF   C G C C G C/G A/C A 
9311 - 095043 
 
PA Hungary NF 
 
C/T G/A C/T C/G G/T C C A/G 
95046 
 
PA Hungary NF 
 
T A T G T C C A 
95049 
 
PA Hungary NF 
 
T A T G T C C A 
95052 
 
PA Hungary NF   T A T G T C C A 
5212 - II.1 (IC) 
 
PA Brazil c.241T>A Y81N C/T G/A C/T C/G G/T C C A/G 
Simplex 
patients 
 
                        
095033 
 
PA Hungary NF 
 
C G C C G C C A 
0910323 
 
PA Hungary NF 
 
C G C C G/T G A A 
0910318 
 
PA Hungary NF 
 
C/T G/A C/T C/G G/T C/G A/C A 
033422 
 
PA Portugal NF 
 
C/T G/A C/T C/G G/T C C A/G 
033423 
 
PA Portugal NF 
 
C G C C G C/G T/C A/G 
040757 
 
PA Portugal c.1064-1076 del Frameshift C G C C G C/G T A 
040758 
 
PA Portugal NF 
 
C/T G/A C/T C/G G/T C/G T/C A 
040759 
 
PA Portugal NF 
 
C/T G/A C/T C/G G/T C/G T/C A 
040760 
 
PA Portugal NF   C G C C G G T A 
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Mutation nomenclature is based on GenBank accession cDNA NM_000104; NF corresponds to Not Found. Patients were diagnosed with PA – Peter´s 
anomaly; EL – Ectopia lentis; Index cases are indicated by IC. The 5 known coding SNPs (printed in bold) with exception for rs2617266 that lies in IVS1 have 
been used to establish CYP1B1 haplotypes. Asterisk corresponds to a regulatory SNP rs2567206 located on promoter region, reported by Chakrabarti et al. 
2010 and SNP rs2551188 which lies within exon I (not translated) have also been used to extended CYP1B1 haplotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular Characterization of a de novo Translocation Associated with Peter´s Anomaly 
 
30 
 
 
 
 
 
 
 
  
Molecular Characterization of a de novo Translocation Associated with Peter´s Anomaly 
 
31 
 
 
 
 
 
 
 
Chapter IV - Discussion 
  
Molecular Characterization of a de novo Translocation Associated with Peter´s Anomaly 
 
32 
 
Here we aimed to described molecular characterization of a female proband with a de novo t(11;18) 
(q23.3q11.2) balanced translocation associated with a syndromic form of Peter´s anomaly (ectopia 
lentis and mild abnormalities in CNS). Fine mapping of breakpoints demonstrated that 11q23.3 
breakpoint lies within a LINE/L2 whereas 18q11.2 breakpoint is surrounded by two Alu repeated 
sequences SINES. This structural genomic information at breakpoint regions suggests a LINE/SINE 
mediated misalignment of the non-homologous chromosomes followed by recombination at 
homologous palindromic sequences. This mechanism has been proposed in chromosome 
translocations implicated repetitive low complexity DNA sequences as targets for chromosome 
disruption and non-homologous recombination (Nambiar and Raghavan, 2011). 
As illustrated in figure 1.2, the 11q23.3 breakpoint maps on a gene rich region and disrupts the IVS3 
of OAF. Despite the fact that OAF is disrupted, Array and RT-qPCR data results revealed that OAF 
gene expression level is considerable unchanged in LCL from proband carrying the t(11;18). 
However this expression value cannot exclude the true functional role of this gene during ocular 
morphogenesis. In human lens epithelium H36CE cell line, moderate gene expression level was 
detected for OAF. This data may suggest a possible role for this gene during lens development. 
Array and RT-qPCR data results indicate that CYP1B1 (cytochrome P450, family 1, subfamily 
B, polypeptide 1, from chromosome 2p22.2) and EDIL3 (EGF-like repeats and discoidin I-like domains 
3, from chromosome 5q14) gene expression levels are altered in LCL from proband carrying the 
t(11;18) translocation. 
In addition, mutation screening of CYP1B1 was performed and no pathogenic mutation was identified 
in proband, although, in 15 subjects affected with Peter´s anomaly, we found a disease-causing 13 nt, 
homozygous deletion in exon 3 (NM_000104.3:c.1064-1076delGAGTGCAGGCAGA) identified in a 
Portuguese patient with PA as well as a missense heterozygous mutation resulting in a tyr81-to-asn 
(Y81N) substitution identified in a Brazilian patient with PA (data shown in table 1.3).  
Despite these two mutations have been previously described in patients with congenital glaucoma and 
primary adult onset open angle glaucoma, CYP1B1 have also been described as candidate gene for 
Peter´s anomaly (Tang et al, 1996; Abu-Amero et al, 2011; Bejjani et al, 1998; Vincent et al, 2001; 
Churchill and Yeung , 2005).  
It has been suggested that Peter´s anomaly and PCG arise from defective neural crest cell migration 
in the 4th to 7th week of fetal development, during which period the anterior segment of the eye forms. 
By other hand a functional analysis of CYP1B1 deficient mice performed by Libby et al, 2003, revealed 
dysgenesis of trabecular meshwork and absence of Shlemm´s canal, both ocular structures with a 
functional role in regulation of intraocular pressure, and affected in PCG, Peter´s and Axenfeld Rieger 
human anomalies (Cvekl & Tamm, 2004). 
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These result shows that CYP1B1 plays an important role during differentiation of ocular anterior 
segment and in pathogenesis of Peter´s and primary congenital glaucoma may share the same 
development pathway for anterior ocular segment. 
It is possible that EDIL3 may act as a modifier of CYP1B1 mutations causing a spectrum of Peter´s 
like phenotypes. To date a possible functional interaction between CYP1B1 and EDIL3 is still not 
understood. 
EDIL3 maps on 5q14 and encodes a glycoprotein secreted by endothelial cells that binds to integrin 
αvβ3 receptor (Choi et al, 2008; Hidai et al, 1998). EDIL3 is structurally classified as an RGD-binding 
integrin. RGD is a cell binding domain common to any matrix proteins including fibronectin, vitronectin 
and tenascin (Schürpf et al, 2012). It plays an important role in mediating angiogenesis and may be 
important in vessel wall remodeling and development (Penta et al, 1999). 
The integrin is present in both lens epithelial and fiber cells. In fibrotic lens diseases such as posterior 
capsular opacification (PCO) as well as anterior subcapsular cataract (ASC), integrins and matrix 
extracellular changes have been associated with a pathological process of transdifferentiation of lens 
epithelial cells into contractile, α-smooth muscle actin (α-SMA)-expressing myofibroblasts, commonly 
referred to as an epithelial-mesenchymal transition (EMT) (Walker & Menko, 2009).  
The EDIL3 an integrin ligand, is highly expressed in human lens epithelial cell line and (Figure 1.4), a 
deregulation process of EDIL3 likely contribute for abnormalities of lens development, consistent with 
Peter´s anomaly and /or lens dislocation (ectopia lentis). 
Furthermore, the transcription factor coding gene, PR Domain Zinc Finger Protein (PRDM5) with PR 
and zinc finger domains is involved in regulation of extracellular matrix development and maintenance 
and are of particular relevance to the multisystemic connective tissue phenotype of brittle cornea 
syndrome (BCS). Expression microarray analysis on dermal fibroblasts from two BCS patients with 
PRDM5 mutations (deletion of exons 9-14 and c.1768C>T) compared to those from age- and sex-
matched controls, have shown great differences in extracellular matrix molecules in particular genes 
encoding connective tissue components, and molecules regulating cell migration and adhesion such 
as EDIL3 and TGFB2. These downstream molecules may play a common role in epithelial to 
mesenchyme transition pathway during ocular mesenchyme development and differentiation which is 
consistent with BCS phenotype affecting cornea structure and function (Burkitt et al, 2011). 
Furthermore PVRL1 (Poliovirus receptor-related 1) located approximately 500 kb upstream from 
11q23.3 breakpoint, revealed altered gene expression levels in proband (Lopez et al,1995) with 3.5 
fold change in proband relative to control. 
PVRL1 belongs to the nectin subfamily of immunoglobulin-like adhesion molecules that participates in 
Ca2+ - independent cell-cell adhesions. Nectin proteins bind to the actin cytoskeleton through the 
cytoplasmatic adaptor protein afadin. These components constitute a nectin mediated adherens 
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junction mechanism. PVRL1 usually has two sometimes three extracellular immunoglobulin-like loops, 
a single transmembrane domain and a cytoplasmic region that plays a role in the organization of 
adherens junctions and tight junctions in epithelial and endothelial cells through interactions mediated 
by PVRL1/PVRL3 as well as PVRL1 and PVRL4 (Barron et al., 2008) (STRING 9.0; http://string-
db.org/ ) and (KEGG; http://www.genome.jp/kegg/) 
In humans, PVRL1 mutations cause cleft lip and palate/ectodermal dysplasia 1 syndrome (CLPED1) 
(OMIM 225060) as well as non-syndromic cleft lip with or without cleft palate (CL/P). Recently, Lachke 
et al. (2012), described a patient with a balanced, t(1;3)(q31.3;q13.13) translocation, severe bilateral 
congenital cataracts, CNS abnormalities and mild developmental delay. It was proposed that 
translocation breakpoint may affect regulation of PVRL3, located 500 Kb upstream from the 
chromosome 3 breakpoint most likely due to a position effect. PVRL3 was first described as a critical 
gene involved in nectin-mediated cell-cell adhesion mechanism in human ocular development. 
During development, PVRL1 and -3 asymmetrically localize not only at puncta adherentia junctions 
but also at synaptic junctions. Using rat hippocampal neurons in culture, Mizoguchi et al., (2002) 
observed that inhibition of the nectin-based adhesion results in a decrease in synapse size and a 
concomitant increase in synapse number. 
PVRL1/ PVRL3 cell-cell interactions have also been identified in anterior lens epithelium and epithelia 
of ciliary body. Both structures are critical for proper development of anterior segment of the eye. 
Recently, Inagaki et al., (2005) investigated the role of PVRL1 and 3 during mouse development. 
Through generation of PVRL1 
-/-
 and PVRL3 
-/-
 mice this author have shown the role of these cellular 
adhesion molecules during ciliary body processes. These mice have shown micropthalmia and 
abnormal morphogenesis of ciliary body due to impairment of apex-apex adhesion between pigment 
and non-pigment cell layers of the ciliary epithelia. These nectin-mediated adhesions are essential for 
the morphogenesis of the ciliary body and may play a role in lens attachment.  
In conclusion we propose that PVRL1 is deregulated most likely due to a cis-ruption mechanism 
triggered by 11q23.3 breakpoint which led to abnormalities affecting lens and CNS development. This 
gene may account for lens dislocation and CNS findings identified in proband. 
By other hand, the chromosome 18q11.2 breakpoint region lies on a gene-poor region, flanked only by 
CTAGE1 and RBBP8. Analysis of expression and functional data for these two genes, available in 
public database resources such as NCBI, EMAGE, MGI, Gene cards, did not revealed expression or 
functional overlap associated with genes implicated in common processes of eye development.  
Comparative genomic analysis in a fragment encompassing 18q11.2 breakpoint region, revealed 
several CNEs across species, with 80% identity (figure 1.3). Two of these CNEs are closely 
surrounding the breakpoint. An interesting hypothesis to elucidate the genetic cause underlying this 
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translocation associated to PA anomaly is the acquisition of a new CNE by the translocated POU2F3 
relocated in a new cis-regulatory environment of derivative chromosome 18. 
Furthermore, POU2F3 gene expression level was almost equal in proband relative to control group. 
However, expression and functional data reviewed for POU2F3 indicated a role involved in regulation 
of keratinocyte differentiation during skin development and wound healing responses (Enomoto et al., 
2003 & Andersen et al., 1997). POU2F3 encodes for an epidermal POU family domain of transcription 
factor. Moreover POU2F3 promoter region was scanned by genomatix
®
 El Dorado promoter analysis 
software and several smad2 and 3 binding-sites were found (data not shown). This apparent upstream 
regulation by TGFβ2 signaling led to hypothesize a functional interaction between these two genes 
during cornea stroma differentiation. 
In fact, Cornea is structured by several layers of epithelia and keratinocytes which exhibit several cell 
phenotypes and states. A critical balance between differentiated and undifferentiated keratinocytes is 
vital for cornea function and for proper extracellular matrix stroma development and maintenance. 
Corneas from conditional targeted TGFβ2 signaling revealed abnormal ECM stroma with a densely 
packed keratinocytes (Itnner et al., 2009). A misexpression regulation of POU2F3 due to relocation of 
this gene in new chromosome context may contribute for molecular pathogenesis of Peter´s anomaly 
associated translocation. 
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Table 1.5 Primers and conditions used to screen CYP1B1 mutations 
Region Primer localization Primer sequence (5´-3´) Exon size 
(bp) 
Annealing T 
(ºC) 
PCR 
size 
(bp) 
5´ UTR CYP1B1 - 5`UTRF CCA GGA AGA CCA CAG AGC CG 5`UTR 64 1813 
  CYP1B1 - 5`UTRR TTC CAC CTC GCT GTA ACC CA       
Promoter_Exon1 CYP1B1 - Ex1F CAC TAC ACT GGC TTT CCG GGA AGC AA 949 64 950 
  CYP1B1 - Ex1R TTC CAC CTC GCT GTA ACC CA       
Exon2 CYP1B1 - Ex2F* TCT CCA GAG AGT CAG CTC CG 1044 60 1230 
  CYP1B1 - Ex2R CTA CTC CGC CTT TTT CAGA       
Exon3 CYP1B1 - Ex3F* GTC ACT GAG CTA GAT AGC CT 829 63 844 
  CYP1B1 - Ex3R GGA CAG TTG ATT TAT GCT CACC       
* Primers used by Abu-Amero et al., 2011 
 
